Antibodies to watch in 2017

ABSTRACT Over 50 investigational monoclonal antibody (mAb) therapeutics are currently undergoing evaluation in late-stage clinical studies, which is expected to drive a trend toward first marketing approvals of at least 6–9 mAbs per year in the near-term. In the United States (US), a total of 6 and 9 mAbs were granted first approvals during 2014 and 2015, respectively; all these products are also approved in the European Union (EU). As of December 1, 2016, 6 mAbs (atezolizumab, olaratumab, reslizumab, ixekizumab, bezlotoxumab, oblitoxaximab) had been granted first approvals during 2016 in either the EU or US. Brodalumab, was granted a first approval in Japan in July 2016. Regulatory actions on marketing applications for brodalumab in the EU and US are not expected until 2017. In 2017, first EU or US approvals may also be granted for at least nine mAbs (ocrelizumab, avelumab, Xilonix, inotuzumab ozogamicin, dupilumab, sirukumab, sarilumab, guselkumab, romosozumab) that are not yet approved in any country. Based on announcements of company plans for regulatory submissions and the estimated completion dates for late-stage clinical studies, and assuming the study results are positive, marketing applications for at least 6 antibody therapeutics (benralizumab, tildrakizumab, emicizumab, galcanezumab, ibalizumab, PRO-140) that are now being evaluated in late-stage clinical studies may be submitted during December 2016* or 2017. Other ‘antibodies to watch' in 2017 include 20 mAbs are undergoing evaluation in pivotal studies that have estimated primary completion dates in late 2016 or during 2017. Of these, 5 mAbs are for cancer (durvalumab, JNJ-56022473, ublituximab, anetumab ravtansine, glembatumumab vedotin) and 15 mAbs are for non-cancer indications (caplacizumab, lanadelumab, roledumab, tralokinumab, risankizumab, SA237, emapalumab, suptavumab, erenumab, eptinezumab, fremanezumab, fasinumab, tanezumab, lampalizumab, brolucizumab). Positive results from these studies may enable submission of marketing applications in 2017 or 2018, or provide justification for additional studies. *See note added in proof for update through December 31, 2016.

[1]  J. Prost,et al.  Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti‐RhD antibody with an optimized Fc for improved engagement of FCγRIII, in healthy volunteers , 2012, Vox sanguinis.

[2]  J. Reichert.  Antibodies to watch in 2016 , 2016, mAbs.

[3]  Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody , 2015, Cancer Immunology Research.

[4]  J. Nezu,et al.  PK/PD analysis of a novel pH-dependent antigen-binding antibody using a dynamic antibody-antigen binding model. , 2016, Drug metabolism and pharmacokinetics.

[5]  J. Reichert.  Antibody-based therapeutics to watch in 2011 , 2011, mAbs.

[6]  G. A. Lazar,et al.  Engineered antibody Fc variants with enhanced effector function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Liedtke,et al.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.

[8]  D. Dodick,et al.  TEV-48125 for the preventive treatment of chronic migraine , 2016, Neurology.

[9]  A. Gottlieb,et al.  Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial , 2015, The British journal of dermatology.

[10]  Tetsuji Sato,et al.  Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. , 2016, The New England journal of medicine.

[11]  G. Linette,et al.  Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[12]  M. Dottore,et al.  Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody. , 2014, Cell reports.

[13]  FDA grants accelerated approval to new treatment for advanced soft tissue sarcoma , 2019, Case Medical Research.

[14]  J. Reichert.  Which are the antibodies to watch in 2012? , 2012, mAbs.

[15]  D. Dodick,et al.  Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study , 2014, The Lancet Neurology.

[16]  C. Brightling,et al.  STRATOS 1 and 2: considerations in clinical trial design for a fully human monoclonal antibody in severe asthma , 2015 .

[17]  M. Obermann,et al.  Faculty Opinions recommendation of TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points. , 2016 .

[18]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[19]  B. Jilma,et al.  Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. , 2016, The New England journal of medicine.

[20]  J. Reichert.  Antibodies to watch in 2010 , 2010, mAbs.

[21]  M. Ng,et al.  A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosus. , 2016, JCI insight.

[22]  J. Silverberg,et al.  Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. , 2016, The New England journal of medicine.

[23]  Janice M Reichert,et al.  Antibodies to watch in 2014 , 2014, mAbs.

[24]  P. O'Byrne,et al.  Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. , 2015, The Lancet. Respiratory medicine.

[25]  Janice M Reichert,et al.  Antibodies to watch in 2015 , 2015, mAbs.

[26]  J. Biedenkapp,et al.  A phase 1 study investigating DX-2930 in healthy subjects. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[27]  H. Ramshaw,et al.  Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC , 2014, Leukemia.

[28]  A. Grauer,et al.  Romosozumab Treatment in Postmenopausal Women with Osteoporosis. , 2016, The New England journal of medicine.

[29]  D. Planchard,et al.  A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study. , 2016, Clinical lung cancer.

[30]  Ulrich Brinkmann,et al.  The making of bispecific antibodies , 2017, mAbs.

[31]  W. Ferlin,et al.  A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2 Study in Children with Primary HLH , 2015 .

[32]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[33]  Janice M. Reichert,et al.  Which are the antibodies to watch in 2013? , 2013, mAbs.

[34]  E. Lee,et al.  Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial , 2016, Annals of the rheumatic diseases.

[35]  T. Igawa,et al.  Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity , 2014, mAbs.